Pharmacokinetic interactions between primaquine and chloroquine

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3354-3359

  Pukrittayakamee, Sasithon ^a   Tarning, Joel ^a,b   Jittamala, Podjanee ^a   Charunwatthana, Prakaykaew ^a   Lawpoolsri, Saranath ^a   Lee, Sue J ^a,b   Hanpithakpong, Warunee ^a,b   Hanboonkunupakarn, Borimas ^a   Day, Nicholas P J ^a,b   Ashley, Elizabeth A ^a,b   White, Nicholas J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 METHOXY 8 QUINOLYLAMINO)VALERIC ACID; ANTIMALARIAL AGENT; CHLOROQUINE; DEETHYLCHLOROQUINE; PRIMAQUINE; UNCLASSIFIED DRUG; 8-(3-CARBOXY-1-METHYLPROPYLAMINO)-6-METHOXYQUINOLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; MALARIA; MALARIA, VIVAX; MIDDLE AGED; PLASMODIUM VIVAX; YOUNG ADULT;

ADULT; ANTIMALARIALS; CHLOROQUINE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PRIMAQUINE; YOUNG ADULT;

EID: 84901280985     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02794-13     Document Type: Article

References (21)

1. World Health Organization. 2010. The treatment of malaria, 2nd ed. WHO, Geneva, Switzerland.
2. White NJ. 1992. Antimalarial pharmacokinetics and treatment regimens. Br. J. Clin. Pharmacol. 34:1-10. http://dx.doi.org/10.1111/j.1365-2125.1992. tb04100.x.
3. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. 1994. Blood stage antimalarial efficacy of primaquine in malaria. J. Infect. Dis. 169:932-935. http://dx.doi.org/10.1093/infdis/169.4.932.
4. Chen G, Geiling EM. 1947. The acute joint toxicity of atabrine, quinine, hydroxyethylapocupreine, pamaquine and pentaquine. J. Pharmacol. Exp. Ther. 91:133-139.
5. Berliner RW, Earle DP, Taggart JV, Welch WJ, Zubrod CG, Knowlton P, Atchley JA, Shannon JA. 1948. Studies on the chemotherapy of the human malarias. VII. The antimalarial activity of pamaquine. J. Clin. Invest. 27:108-113.
6. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 46:301-306.
7. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. 2013. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar. J. 12:212. http://dx.doi.org/10.1186/1475-2875-12-212.
8. U.S. Food and Drug Administration. 2003. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products. U.S. Food and Drug Administration, Washington, DC.
9. U.S. Food and Drug Administration. 2001. Guidance for industry: statistical approaches to establishing bioequivalence. U.S. Food and Drug Administration, Washington, DC.
10. Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS. 1986. Pharmacokinetics of primaquine in patients with P. vivax malaria. Eur. J. Clin. Pharmacol. 31:205-210. http://dx.doi.org/10.1007/BF00606660.
11. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. 19:745-750.
12. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM. 1985. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br. J. Clin. Pharmacol. 19:751-755.
13. Kim YR, Kuh HJ, Kim MY, Kim YS, Chung WC, Kim SI, Kang MW. 2004. Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. Arch. Pharm. Res. 27:576-580. http://dx.doi.org/10.1007/ BF02980134.
14. Singhasivanon V, Sabcharoen A, Attanath P, Chongsuphajaisiddhi T, Diquet B, Turk P. 1991. Pharmacokinetics of primaquine in healthy volunteers. Southeast Asian J. Trop. Med. Public Health 22:527-533.
15. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, Edstein MD. 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br. J. Clin. Pharmacol. 61:682-689. http://dx.doi.org/10.1111/j.1365-2125.2006.02601.x.
16. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD. 2009. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am. J. Trop. Med. Hyg. 81:747-753. http://dx.doi.org/10.4269/ajtmh.2009.09-0214.
17. Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TME, White NJ. 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br. J. Clin. Pharmacol. 35:193-198. http://dx.doi.org/10.1111/j.1365-2125.1993.tb05685.x.
18. Blessborn D, Neamin G, Bergqvist Y, Lindegardh N. 2006. A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J. Pharm. Biomed. Anal. 41:207-212. http://dx.doi.org/10.1016/j.jpba.2005.10.018.
19. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 44: 1680-1685. http://dx.doi.org/10.1128/AAC.44.6.1680-1685.2000.
20. Zsila F, Visy J, Mady G, Fitos I. 2008. Selective plasma protein binding of antimalarial drugs to alpha 1-Acid glycoprotein. Bioorg. Med. Chem. 16:3759-3772. http://dx.doi.org/10.1016/j.bmc.2008.01.053.
21. White NJ. 2007. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7:549-558. http://dx.doi.org/10.1016/S1473-3099(07)70187-1.